0.00Open0.00Pre Close0 Volume0 Open Interest370.00Strike Price0.00Turnover77.51%IV-46.20%PremiumDec 20, 2024Expiry Date116.93Intrinsic Value100Multiplier20DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9918Delta0.0017Gamma2.16Leverage Ratio-0.0133Theta-0.0270Rho-2.15Eff Leverage0.0116Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet